Kornimate/medical-research-clean huggingface dataset:
magnetic brain stimulation for the treatment of adult depression

Conditions: Depression

Summary: this study will evaluate the safety and effectiveness of magnetic brain stimulation for the treatment of major depression in depressed adults with moderate treatment resistance.

major depression is a type of depression that can interfere with the ability to work, study, sleep, eat, and enjoy once pleasurable activities. because people often develop resistances to medications used to treat depression, new treatments are needed. decreased electrical activity in the prefrontal region of the brain has been linked to some symptoms of depression. repetitive transcranial magnetic stimulation (rtms) can be used to influence the brain's electrical activity. this procedure entails attaching electrodes to the head and using a device to pass magnetic energy through coils and into the brain. rtms has been shown to have antidepressant effects in depressed individuals. however, optimal levels of intensity and treatment duration have yet to be determined. this study will assess the safety and effectiveness of rtms on the prefrontal region of the brain in depressed adults with moderate treatment resistance. the treatment phase of this double-blind study will last a minimum of 32 weeks and will consist of 3 phases. in phase i, participants will be randomly assigned to receive either rtms or sham stimulation. the sham stimulation will mimic the sensation of rtms but will not induce an intracerebral current. treatments will be administered daily for 3 weeks. participants who show signs of improvement may continue phase i for up to 3 additional weeks. in phase ii, participants who were unresponsive to phase i treatment will receive daily rtms at a lower dose for 3 weeks. participants who show signs of improvement, but have not achieved remission, may continue phase ii for 4 additional weeks. baseline magnetic resonance images will be used to determine the optimal stimulus intensity by adjusting for individual differences in cortical to skull distances. phase iii participants will be only those who achieved remission in the first 2 phases. these participants will receive antidepressant medication treatment daily for six months. participants' functional status and symptoms of depression will be measured using self-report scales and video-recorded interviews at study start date and at the end of each treatment phase.

Eligibility criteria:
inclusion criteria: * diagnosis of major depression with a current episode * hamilton rating scale for depression score higher than 20 * no response or intolerance to antidepressant medication in the current depressive episode exclusion criteria: * current use of antidepressants * diagnosis of psychosis or anxiety disorder * current substance abuse * seizures or history of head trauma

Keywords: electric stimulation magnetic stimulation prefrontal cortex brain
are ck+/cd45+ double-positive circulating cells of tumor-origin? characterization in metastatic breast cancer

Conditions: Metastatic Breast Cancer

Summary: a prospective, single-centre, proof-of-concept pilot study in patients with metastatic breast cancers (mbc) (whatever the immunohistochemical subtype) treated at the iuct-o. eligible patients will be selected and informed of this study during a medical consultation for cancer that has metastasised, has relapsed or is progressing metastatically, by medical oncologists at the oncopole claudius regaud (ocr). then, with the patient's agreement and before the start of anti-tumour treatment, a blood sample will be taken to detect dp-circulating cells. a breast cancer tumour sample (non-bone metastasis or, failing that, primary tumour) must be available (ffpe archived tumour block). each patient will participate in the study for one day. 60 patients will be included in this interventional study.


Eligibility criteria:
inclusion criteria: 1. patients with metastatic breast cancer eligible for 1st, 2nd or 3rd line treatment at stage iv, regardless of immunohistochemical subtype (triple-negative, rh+/her2-negative or her2-positive). 2. patient with metastatic disease or metastatic relapse or progression who has not yet started 1st line treatment for metastatic disease or line 2 or line 3. 3. tumour sample available (archived tumour block): non-bone metastasis preferred if available or, failing this, primary breast tumour. 4. age ≥ 18 years and who ≤ 2. 5. patient affiliated to a french social security scheme. 6. patient having signed his/her informed consent prior to inclusion in the study and prior to any specific procedure for the study. exclusion criteria: 1. associated pathology(ies) likely to prevent the study procedure from running smoothly. 2. any psychological, family, geographical or sociological condition that prevents compliance with the medical monitoring and/or procedures set out in the study protocol. 3. patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship, protection of justice). 4. patient who has presented with another solid tumour (excluding carcinoma in situ of the breast or cervix) within 5 years. 5. pregnant patient.

Keywords: metastatic breast cancer ck+/cd45+ double-positive circulating cells
efficacy of high and low intensity percutaneous electrolysis for the treatment of myofascial pain syndrome

Conditions: Knee Pain Chronic; Muscle Pain

Summary: muscle pain is frequently attributed to myofascial pain syndrome (mps) in which myofascial trigger points (mtrp) are a characteristic feature. dry needling is a frequent clinical practice to manage mps but few evidence is published about percutaneous electrolysis effects for the treatment of mps. this is a randomized clinical trial with 3 parallel groups: 1) high intensity-short time percutaneous electrolysis; 2) low intensity-long time percutaneous electrolysis; 3) dry needling control group.

the current study aimed to evaluate changes in rectus femurs active trigger points and patellar tendon pain pressure thresholds and subjective anterior knee pain perception after application of two percutaneous electrolysis methods using a same charge (high intensity and low intensity) compared to a dry needling group in patients with patellofemoral pain syndrome (pfps) fifteen patients diagnosed with unilateral pfps were divided in two experimental groups (high intensity percutaneous electrolysis and low intensity percutaneous electrolysis) and one active control group (dry needling. the duration of the study was 7 days with only one intervention. pain pressure thresholds were assessed using an algometer before the intervention, immediately after the intervention and after 7 days and a visual analogue scale was used before the treatment and after 7 days to rate the subjective anterior knee pain perception. also a vas was used to rate the pain perception during the intervention

Eligibility criteria:
inclusion criteria: * athletes with knee pain * presence of at least one active trigger point exclusion criteria: * farmacologic treatment * surgery or traumas * skin alterations or infections * prior 6 weeks dn nor pt treatment

Keywords: patellofemoral pain syndrome electrolysis myofascial pain syndromes acupuncture
characterization of the interruptions of the gaa expansion and study of their influence on the severity of friedreich's ataxia

Conditions: Friedreich Ataxia

Summary: friedreich's ataxia (fa) is the most frequent recessive genetic ataxia with an estimated prevalence of 1/50 000. the first symptoms appear around the age of 10 years with a progressive course and the need for an armchair 10- 15 years after the first symptoms. more rarely the disease can present with a late onset (after the age of 25) with a picture characterized by spastic paraparesis and slower progression ("lofa" for "late onset friedreich ataxia" or vlofa for "very late appearance of friedreich's ataxia "). af is caused in 96% of cases by an expansion of gaan triplets (n\> 100 repeats) located in intron 1 of the fxn gene, present on the two alleles, and, in the rest of the cases, by an associated expansion a point mutation or a deletion in trans. during molecular diagnostics, it is not uncommon to find the presence of interruptions within the gaa expansion. this results in the absence and / or the shift of peak (s) within the chromatogram. to date, only the partial correlation between the size of the expansion and the age of onset of friedreich's ataxia has been established. in particular, very atypical forms of af with a late onset (after the age of 25) are in particular explained by the low number of repetitions in the expansion, typically between 100 and 500 repetitions. however, the presence of an interruption could stabilize the size of the expansion and, therefore, be mainly associated with expansions of small sizes and therefore with a late onset of the disease. the objective of this study is therefore to analyse and caracterize the presence and the type of interruptions of the gaa expansions in a group of patients with fa ; this data will be correlated with the age at onset of fa.


Eligibility criteria:
inclusion criteria: * subjects with diagnosis of genetically confirmed friedreich's ataxia (af) and : * two expansions of gaan triplets (\> 100 repetitions or "premutation", corresponding to\> 32 but \<100 repetitions) located in intron 1 of the fxn gene present on the two alleles; * symptomatic (sara scale\> 4); * having signed a consent for the performance of genetic analyzes which also includes the authorization for the conduct of further studies for research purposes and the authorization for the collection, entry and computer processing of medical data, in all confidentiality. a newsletter on the principle of non-opposition will be sent. exclusion criteria: * patients with friedreich's ataxia due to an expansion associated with a point mutation or a deletion in trans; * patients who, at the time of signing the genetic consent, objected to the use of their data for research purposes.

Keywords: neurology genetic friedreich ataxia
a study to evaluate tobevibart + elebsiran in chronic hdv infection

Conditions: Viral Hepatitis

Summary: this is a multicenter, open label, randomized phase 3 clinical study to evaluate the efficacy and safety of the combination of tobevibart + elebsiran for the treatment of chronic hepatitis delta in comparison to delayed treatment.


Eligibility criteria:
inclusion criteria: 1. male or female ages 18 to 70 years at screening 2. chronic hdv infection for \>/= 6 months 3. on nrti therapy against hbv for at least 12 weeks prior to day 1 or have hbv dna \< 20 iu/ml at screening, currently on locally approved nrti therapy 4. serum alt \> uln and \< 5x uln 5. non-cirrhotic or compensated cirrhotic liver disease at screening exclusion criteria: 1. any clinically significant chronic or acute medical or psychiatric condition that makes the participant unsuitable for participation. 2. history of significant liver disease from non-hbv or non-hdv etiology 3. history of allergic reactions, hypersensitivity, or intolerance to study drug, its metabolites, or excipients. 4. history of anaphylaxis 5. history of immune complex disease 6. history of autoimmune disorder 7. history or evidence of alcohol or drug abuse within 6 months before screening or a positive drug screen at screening unless it can be explained by a prescribed medication

Keywords: hdv hepatitis d virus hepatitis chronic hepatitis d virus hepatitis d hepatitis d, chronic hepatitis delta virus
esomeprazole with sildenafil citrate in women with early-onset preeclampsia

Conditions: Preeclampsia

Summary: previous studies have shown that expectant management of preeclampsia in the context of extreme prematurity may improve perinatal outcomes. indeed, it has been estimated that for each additional day of pregnancy prolongation between 24 and 32 weeks of gestation, there is a nonlinear corresponding gain of 1% in fetal survival. in this study, we evaluate the use of esomeprazole alone or with sildenafil citrate for the treatment of singleton pregnancies complicated by preeclampsia. we hypothesized that the potential increase in uteroplacental and fetoplacental blood flow with the use of esomeprazole alone or with sildenafil citrate may be associated with pregnancy prolongation (the primary study outcome) and improved maternal and perinatal outcomes.

the etiology and pathophysiology of preeclampsia have not been clearly established; impaired immunologic adaptation and genetic incompatibility seem to be involved in deficient trophoblastic implantation. placental hypoxia and endothelial dysfunction may lead to preeclampsia through an exacerbated systemic inflammatory reaction. increased placental expression and secretion of soluble fms-like tyrosine kinase 1 appear to play a central role in the pathogenesis of preeclampsia. the soluble fms-like tyrosine kinase 1 antagonizes the proangiogenic biologic activity of circulating vascular endothelial growth factor and placental growth factor, leading to a failure of nitric oxide signaling to smooth muscle the investigators will conduct a randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of esomeprazole alone or with sildenafil citrate in preterm pregnancies complicated by preeclampsia.

Eligibility criteria:
inclusion criteria: * pregnant women presenting at a gestational age between 28 + 0 weeks and 32 + 0 weeks presented with preterm preeclampsia * the patient will be managed with an expectant management * give written informed consent exclusion criteria: * multiple pregnancies. * previous hypersensitivity reaction esomeprazole or sildenafil citrate * contraindications to the use of esomeprazole or sildenafil citrate * the patient is unable or unwilling to give consent * an established fetal compromise that necessitates delivery

Keywords: esomeprazole sildenafil citrate preterm preeclampsia
pain processing and pain reporting in patients with alzheimer's disease

Conditions: Pain

Summary: the study investigates pain processing and pain reporting in patients with alzheimers disease compared to healthy participants. employing a within-subject design, the study includes patients with alzheimers disease and healthy participants that are exposed to thermal stimuli. during the test session the facial expressions of the participant are video recorded. by repeating this on separate test days, the involvement of pain relief and pain increase is investigated.


Eligibility criteria:
inclusion criteria: * mild to moderate patients with alzheimers disease (group 1) * healthy participants ( group 2) exclusion criteria: * chronic pain conditions * other medical, psychiatric or neurological disorders * use of pain-reliving medication 24 hours prior to testing

Keywords: pain alzheimers disease
integration of buprenorphine into hiv clinical settings - primary care model (pcm)

Conditions: Buprenorphine; HIV; Drug Abuse; Drug Addiction; Drug Dependence; Drug Use Disorders; Drug Use Disorder; Substance Abuse; Opiate Addiction; Substance-related Disorders

Summary: the purpose of this study is to assess the feasibility, cost and effectiveness of interventions designed to integrate buprenorphine treatment for opioid dependence into hiv primary care in ten hiv care centers in the u.s. in the site led by dr. altice, we compare two models of providing hiv care and buprenorphine treatment. assignments are based on participants' city of residence. in the onsite (integrated care) model, participants receive buprenorphine, substance abuse counseling and hiv care at one location: the waterbury hospital infectious disease clinic. in the off-site model (non-integrated care) buprenorphine induction, substance abuse counseling, and hiv care will be provided at separate locations: the community health care van (chcv), the yale aids program, and patients' own hiv providers, respectively. data is collected from interviews with participants, reviews of medical records, and surveys and interviews with clinicians.


Eligibility criteria:
inclusion criteria: * hiv-infected * clinical diagnosis of opioid dependence * fluent in english or spanish * 18 years or older exclusion criteria: * liver function tests (transaminase only) at five times or higher than normal level; * diagnostic and statistical manual of mental disorders-fourth edition (dsm-iv) criteria for benzodiazepine abuse or dependence within the past 6 months; * dsm-iv criteria for alcohol dependence within the past 6 months; * actively suicidal; * psychiatric impairment that impedes ability to consent (dementia, delusional, actively psychotic); * methadone dose exceeding levels allowing for safe transition to buprenorphine; * pregnant women and women actively trying to become pregnant; * clinical judgment of local site principal investigator that patient is inappropriate

Keywords: buprenorphine hiv drug abuse drug addiction drug dependence drug use disorders drug use disorder substance abuse opiate addiction substance-related disorders
a study of standard treatment +/- enoxaparin in small cell lung cancer

Conditions: Small Cell Lung Cancer

Summary: the endpoint is to investigate if the addition of low molecular heparin - enoxaparin, will result in a significant increase of overall survival in patients with small cell lung cancer, receiving standard chemotherapy.

chemotherapy will be given in accordance with local or regional guidelines but shall include a platinum drug + any topoisomerase inhibitor. within these limits the study will accept different local variants as long as each centre remains consistent to its declared standard chemotherapy regimen. the recommended regimen is carboplatin or cisplatin plus etoposide q3 weeks for 4 cycles but up to 6 cycles is allowed. local dosages and dose reduction schedules will be used.

Eligibility criteria:
inclusion criteria: 1. histologically or cytologically verified sclc, all stages 2. who performance status 0, 1, 2 or 3 3. age 18 years or older 4. intention and feasibility to treat with chemotherapy consisting of platinum + topoisomerase inhibitor. 5. platelets \>100 x109 /l 6. signed informed consent 7. pk (prothrombin complex) inr and aptt within normal ranges. exclusion criteria: 1. prior systemic chemotherapy for lung cancer. 2. concomitant anticoagulation treatment, except for asa or clopidogrel 3. active overt bleeding of clinical importance or at high risk (e.g. earlier observed haemorrhage in a brain metastasis, severe coagulopathy as haemophilia, severe liver dysfunction with impaired coagulation, acute peptic ulcer, and within the last 3 months suffered from intracranial haemorrhage, or surgery in the central nervous system). 4. any other known contraindication for enoxaparine ( e.g. hypersensitivity against enoxaparine and its derivatives). 5. pregnancy or breast-feeding 6. fertile women not using effective contraceptives or men who do not agree to use effective contraception during the treatment period. 7. treatment with any other investigational agent, or participation in any other clinical trial.
the effect of exercise on gut microbiota in type 2 diabetic patients

Conditions: Type 2 Diabetes Mellitus; Insulin Sensitivity/Resistance

Summary: to investigate whether targeted lifestyle intervention (exercise), induces a change in intestinal fecal microbiota related to improved glycemic control and systemic inflammation in patients with dm type 2.

diet and exercise are the most beneficial lifestyle interventions in patients with diabetes mellitus (dm) type 2, causing an increase in glucose tolerance. one of the mechanisms through which these treatment modalities work might be explained through changes in the gut microbiota. recent studies show that the chronic inflammatory status causing insulin resistance in dm type 2, is triggered by an increase in circulating bacterial lipopolysaccharide (lps). strict lifestyle intervention, such as exercise, so called diabetes bootcamp (db), may manipulate the gut microbiota, reducing circulating lps, causing an improvement of the insulin-mediated

Eligibility criteria:
inclusion criteria: * subjects must meet the criteria for diabetes type 2 (a random blood sugar of \> 11.1 mmol/l and/or a fasting blood sugar lever of \>7.0 mmol/l and/or a blood sugar of \>11.1 mmol/l two hours after an oral glucose tolerance test and/or an hba1c level of \>47 mmol/mol). * male or female (post-menopausal) * age above 45 years and below 70 years * bmi \>30 kg/m2 * hba1c \< 80 mmol/mol or \< 8,6% subjects must use metformin * stable medication use * stable tension regulation (with or without medication) * subjects should be able to give informed consent exclusion criteria: * a history of cardiovascular event (cerebrovascular event, myocardial infarction or pacemaker implantation) * severe-very severe lung emphysema (gold stage iii-iv) * use of any antibiotics or proton pump inhibitor (ppi) in the past three months * use of any other antidiabetic medication besides metformin (e.g. su-derivates, insulin) * use of a platelet inhibitor or cumarin derivate during * subjects participated in a lifestyle programme in the past 6 months (diet or exercise)

Keywords: gut microbiota
comparison of the effects of static and pnf hamstring stretching exercises in patients with knee osteoarthritis

Conditions: Knee Osteoarthritis

Summary: the aim of this study is to determine and compare the effects of static and pnf hamstring stretching exercises on joint pain, hamstring flexibility and functional status in patients with knee osteoarthritis.

a total of 36 patients between the ages of 40 and 75 who were diagnosed with kellgren-lawrence stage ii and iii knee oa by the physician were included in the study. participants were divided into two groups as static stretching group or pnf stretching group. patients' demographic and clinical information was recorded. pain intensity was evaluated with visual pain scale, hamstring flexibility with active knee extension test, functional status with western ontario and mcmasters university osteoarthritis index and timed get up and go test. in addition to the standard physiotherapy program, the subjects practiced stretching exercises according to the groups that they've been separated. evaluations were repeated in the end of the treatment and in the follow-up.

Eligibility criteria:
inclusion criteria: * individuals with knee osteoarthritis severity ii, iii, or iv according to the kellgren-lawrence classification, * individuals with positive active knee extension test, * individuals with a body mass index of 30 or less, * individuals with a pain severity of at least 3/10 according to the visual pain scale. exclusion criteria: * individuals with health problems that prevent them from doing the evaluations and exercises to be used in the study, * individuals who exercise regularly for the last six months, * individuals with a diagnosis of neurological disease affecting the lower extremity.

Keywords: knee osteoarthritis hamstring stretching